selective RORgt inverse agonist

entered clinical dev. (psoriasis), discontinued

from HTS and SBDD

ACS Med. Chem. Lett., Apr. 10, 2020

Bristol Myers Squibb, Princeton, NJ


BMS-986251 is an inverse agonist of RORgt, a hot target in inflammation for a significant period. Unfortunately it looks like development hit a wall in this space, and several publications…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: